At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 133 enrolled
Drug / intervention
Perampanel +1 moredrug
Likely dose
Perampanel 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to Less Than 18 Years of Age) With Inadequately Controlled Partial-onset Seizures
In Brief
A Phase 2 clinical trial evaluating Perampanel and Placebo for Epilepsy. Completed, enrolled 133 participants across 37 sites in 11 countries.
Detailed Summary
This study is designed to investigate the short- and long-term effects of perampanel on cognition, growth, and development in adolescents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesAustralia, Belgium, Czechia, Hungary, India, Latvia, Poland, South Korea, Spain, Thailand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartSep 2010
Primary CompletionJun 2013
Study CompletionNov 2014
TodayJul 2026
First PostedJul 13, 2010
Enrollment StartSep 1, 2010
Primary CompletionJun 1, 2013
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.0 years ago
Interventions
Perampaneldrug
2 mg titrated up to 8-12 mg maximum; taken once daily.
Placebodrug
Matching Placebo taken once daily.